雷诺氏现象可分为初期(原发期)或自发病(60％～80％)和二期(继发期,25％～30％)。二期型病可能是局部起因(轻外伤,腕管压迫,胸腔出口综合征)或有一般或全身原因(药疗法中毒,胶原病,特别是硬皮病和播散的红斑狼疮,增生的或退化的动脉病和动脉炎,内分泌或代谢病)。此病的二期型通常称为雷诺氏综合征,而一期型称为雷诺氏病。吡拉西坦已用于治疗初期和二期雷诺氏现象,进行三个连续和补充治疗研究。首次研究在20例有初期雷诺现象的病人,利用临床和超声检查,毛细血管镜和实验室试验,以 Raynaud’s phenomenon can be divided into initial (primary) or spontaneous disease (60% ~ 80%) and two (secondary period, 25% to 30%). Stage II disease may be a local cause (light trauma, carpal tunnel compression, thoracic outlet syndrome) or general or systemic causes (pharmacotoxicity, collagen disease, especially scleroderma and disseminated lupus erythematosus, hyperplastic or Degenerative arterial disease and arteritis, endocrine or metabolic disease). The disease is often called the second phase of Raynaud’s syndrome, while the first phase is called Raynaud’s disease. Piracetam has been used in the treatment of primary and secondary Raynaud’s disease and undergoes three consecutive and supplementary treatment studies. The first study of 20 patients with an initial Renault phenomenon, using clinical and ultrasonographic, capillary and laboratory tests to